<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01155908</url>
  </required_header>
  <id_info>
    <org_study_id>AA15736</org_study_id>
    <nct_id>NCT01155908</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of 10 mg Amlodipine Besylate/ 20 mg Benazepril Hydrochloride Capsules of Dr.Reddys Laboratories Limited Under Non-fasting (Fed) Conditions</brief_title>
  <official_title>Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of 10 mg Amlodipine Besylate/20 mg Benazepril Hydrochloride Capsules in Healthy Adult Male Volunteers Under Non-fasting (Fed) Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr. Reddy's Laboratories Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dr. Reddy's Laboratories Limited</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to compare the single-dose relative bioavailability of Dr.
      Reddy's Laboratories, Ltd. and Lotrel速) 10 mg amlodipine besylate/20 mg benazepril
      hydrochloride capsules, under non-fasting (fed) conditions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Comparative, Randomized, Single-Dose, 2-way Crossover Bioavailability Study of Dr. Reddy's
      Laboratories, Ltd. and Novartis (Lotrel速) 10 mg Amlodipine Besylate / 20 mg Benazepril
      Hydrochloride Capsules in Healthy Adult Male Volunteers under non-fasting (fed) Conditions
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2005</start_date>
  <completion_date type="Actual">May 2005</completion_date>
  <primary_completion_date type="Actual">May 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioavailability based on Cmax and AUC parameters</measure>
    <time_frame>2 Months</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Amlodipine Besylate/Benazepril Hydrochloride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg Amlodipine Besylate/20 mg Benazepril Hydrochloride Capsules of Dr.Reddy's Laboratories Limited</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lotrel</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lotrel速 (10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules) of Novartis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amlodipine Besylate / Benazepril Hydrochloride</intervention_name>
    <description>10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules</description>
    <arm_group_label>Amlodipine Besylate/Benazepril Hydrochloride</arm_group_label>
    <arm_group_label>Lotrel</arm_group_label>
    <other_name>Lotrel速 (10 mg Amlodipine Besylate / 20 mg Benazepril</other_name>
    <other_name>Hydrochloride Capsules)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Healthy adult male volunteers of 18-55 years of age;

          -  Weighing at least 60 kg within 15% of their ideal weights (Table of &quot;Desirable Weights
             of Adults&quot; Metropolitan Life Insurance Company 1983)

          -  Medically healthy subjects with clinically normal laboratory profiles and ECGs;

          -  Voluntarily consent to participate in the study.

        Exclusion Criteria:

        - History or presence of significant cardiovascular, pulmonary, hepatic renal,
        hematologic,gastrointestinal, endocrine, immunologic, dermatologic, neurologic or
        psychiatric disease.

          -  History or presence of:

               -  alcoholism or drug abuse within the past year;

               -  hypersensitivity or idiosyncratic reaction to amlodipine or other calcium channel
                  blockers;

               -  hypersensitivity or idiosyncratic reaction to benazepril HCl, benazeprilat or
                  other ACE inhibitors.

               -  angioedema or anaphylactic reaction to any substance;

          -  Subjects whose sitting blood pressure is less than 110/60 mmHg at screening or 100/55
             mmHg before dosing.

          -  Subjects whose pulse is lower than 55 b.p.m. at screening or 50 b.p.m. prior to
             dosing.

          -  Subjects who have used any drugs or substances known to be strong inhibitors of CYP
             enzymes (formerly known as cytochrome P450 enzymes) within 10 days prior to the first
             dose.

          -  Subjects who have used any drugs or substances known to be strong inducers of CYP
             enzymes (formerly known as cytochrome P450 enzymes) within 28 days prior to the first
             dose.

          -  Subjects who have vomited, who have experienced diarrhea or who have undergone
             vigorous and prolonged exercise (without drinking) within 24 hours prior to dosing.

          -  Subjects who have been on a special diet (for whatever reason) during the 28 days
             prior to the first dose and throughout the study.

          -  Subjects who, through completion of the study, would have donated in excess of: 500 mL
             of blood in 14 days; 1500 mL of blood in 180 days; 2500 mL of blood in 1 year.

          -  Subjects who have participated in another clinical trial within 28 days prior to the
             first dose.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gaetano Morelli, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>MDS Pharma Services</affiliation>
  </overall_official>
  <verification_date>July 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 1, 2010</study_first_submitted>
  <study_first_submitted_qc>July 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 2, 2010</study_first_posted>
  <last_update_submitted>July 1, 2010</last_update_submitted>
  <last_update_submitted_qc>July 1, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Senior Manager -Research &amp; Development</name_title>
    <organization>Dr. Reddy's Laboratories Limited</organization>
  </responsible_party>
  <keyword>Bioavailability</keyword>
  <keyword>10 mg Amlodipine besylate/20 mg benazepril hydrochloride capsules</keyword>
  <keyword>Crossover</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benazepril</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

